The implementation of HB 988 is anticipated to significantly impact state laws governing health insurance and patient protections. By instituting a separate out-of-pocket maximum for prescription drugs, the bill seeks to improve access to medications and make healthcare more affordable for residents. This change could create a more standardized approach to how insurance companies handle drug coverage, thereby providing a clearer framework for policyholders regarding their financial responsibilities. It is expected to predominantly affect the financial practices of insurance providers operating within Massachusetts.
Summary
House Bill 988, titled 'An Act Relative to Patient Financial Protection', aims to enhance the financial protections for patients in Massachusetts regarding prescription drugs, including specialty drugs. The bill mandates that all health insurance policies, contracts, or agreements that provide coverage for prescription drugs must establish a separate out-of-pocket limit specifically for these medications. This limit cannot exceed the minimum annual deductible for high-deductible health plans as outlined in federal regulations. This aims to ensure that patients are not excessively burdened by high out-of-pocket expenses when it comes to their necessary medications.
Contention
Despite the proposed benefits of HB 988, some contention may arise surrounding its implementation. Critics might argue that establishing separate out-of-pocket limits could increase insurance premiums as companies adjust their policies to comply with the new regulations. There may also be debates regarding whether these regulatory measures might inadvertently limit insurance choices for consumers, as providers may seek to avoid covering high-cost specialty drugs altogether due to the increased financial risk. Legislative discussions will likely reflect a balance between protecting patients financially and ensuring insurance market stability.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Prescriptions for testosterone not allowed to be transmitted or reported within the prescription drug monitoring database and removes from the records all existing information concerning prior testosterone prescriptions.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a sixty-day (60) supply may be dispensed at any one time.
Increases the maximum fill for non-opioid, non-narcotic controlled substances found in schedule II, so that a ninety-day (90) supply may be dispensed at any one time.